SOURCE: Acceleron Equity Research

October 01, 2014 11:32 ET

Coverage Initiation Report Focuses on CEL-SCI Corporation

NEW YORK, NY--(Marketwired - Oct 1, 2014) - CEL-SCI Corporation (NYSE MKT: CVM) is the subject of an in-depth initiation coverage report by Acceleron Equity Research.

Interested investors may get more information and a copy of the coverage report at http://acceleronequity.net/Acceleron_CVMReport.pdf

  • CEL-SCI Corporation is conducting the world's largest Phase III trial for the treatment of head and neck cancer, a $6 Billion market. 6% of cancers are head and neck cancer, accounting for 600,000 new cases each year. If CVM's drug Multikine® (Leukocyte Interleukin, Injection) proves to be effective, it would become a new way to treat head and neck cancer, by using the body's own immune defense system.

  • The Phase III trial has already enrolled more than 25% of the planned 880 patients. CVM is on track to complete patient enrollment by the end of 2015. The trial is already active in 17 countries on 3 continents.

  •  CVM's Multikine® immune therapy makes tumors that are normally invisible to the immune system visible. Multikine® can therefore be used as a first line treatment before surgery, radiation, or chemotherapy.

  • Multikine® is being tested in a Phase I trial with the U.S. Navy for the treatment of anal warts in HIV/HPV co-infected patients. HPV is the most common sexually transmitted disease and can lead to cancer. There is currently no effective treatment for anal warts in HIV/HPV co-infected patients and the company has just announced that the first volunteer patient has been enrolled and administered Multikine® as part of a Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD).

  • CEL-SCI Corporation has a manufacturing facility ready for $3 Billion worth of production.

About Acceleron Equity Research

Acceleron is a market intelligence service that focuses on identifying and analyzing technically-complicated companies and equities. Acceleron offers a subscription model product to investors and funds with an emphasis in the emerging markets.

Contact Information

  • Media Contact:

    Mike Morhamus
    Acceleron Equity Research
    855-216-8786